HIGHLIGHTS
- who: Jason J. Luke from the (UNIVERSITY) have published the Article: Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors, in the Journal: (JOURNAL) of 12/Dec/2022
- what: Clinical data on the antitumor activity of combination treatment with an epigenetic modulator and an immune checkpoint inhibitor were limited at the time when this study was designed. The study was initiated on February 27, 2017, and a strategic decision was made on April 11, 2018, to permanently stop enrollment.
- how: With the exception of MSS CRC these tumor . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.